Press Releases

04.29.2020

BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany

04.28.2020

PFIZER REPORTS FIRST-QUARTER 2020 RESULTS

04.23.2020

Pfizer Hosts Virtual-Only Annual Meeting of Shareholders

04.22.2020

FoRx Therapeutics AG Raises EUR 10 Million Seed Round to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer

04.22.2020

BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates

04.20.2020

Valneva Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15

04.09.2020

Pfizer Advances Battle Against COVID-19 on Multiple Fronts

04.09.2020

Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development

04.08.2020

U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy

04.07.2020

Pfizer to Hold Virtual-Only 2020 Annual Meeting of Shareholders

04.06.2020

Pfizer and The Pfizer Foundation Donate $40 Million in Charitable Grants, Expand Product Access and Mobilize Colleagues to Combat COVID-19 Pandemic

04.02.2020

Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)